DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group

Archives of Neurology

Abstract

DATATOP (Deprenyl and tocopherol antioxidative therapy of parkinsonism) is a placebo-controlled clinical trial designed to test the hypothesis that long-term treatment of patients with early Parkinson's disease with deprenyl 10 mg/d and/or tocopherol (vitamin E) 2000 IU/d will extend the time until disability requires therapy with levodopa (primary end point). At 28 US and Canadian sites, 800 eligible patients in the early stages of untreated Parkinson's disease were enrolled in DATATOP and randomized to (1) active deprenyl, (2) active tocopherol, (3) active deprenyl and tocopherol, or (4) placebo treatments. Subjects are being evaluated systematically at regular intervals over 2 years to determine if and when the primary end point of disability is attained. At baseline evaluation, our cohort represented minimally disabled patients with Parkinson's disease who did not require symptomatic anti-Parkinson's disease medications. Despite an almost 2:1 representation of male-female subjects, no selection biases were identified that might confound the primary end-point analysis. This large DATATOP cohort is expected to provide a high likelihood (power) for detecting significant treatment effects, if indeed they exist.

Citations

Dec 7, 2013·Journal of Neural Transmission·E A EspinerT J Anderson
Oct 16, 2010·Biomarkers in Medicine·Sara CiprianiMichael A Schwarzschild
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·T HersheyJ S Perlmutter
May 13, 1997·Proceedings of the National Academy of Sciences of the United States of America·G CohenN Kesler
Jan 13, 2011·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Dawn S Knudsen Gerber
Nov 30, 2014·Neurologic Clinics·Christiana Ossig, Heinz Reichmann
Feb 1, 1996·Journal of Neurology, Neurosurgery, and Psychiatry·V BocolaN Martucci
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Andrew Feigin
Dec 20, 2007·European Journal of Clinical Pharmacology·Nick Holford, John G Nutt
Apr 17, 2008·Archives of Neurology·Michael A SchwarzschildJohn Ondrasik
Jan 8, 2009·JAMA : the Journal of the American Medical Association·Frances M WeaverUNKNOWN CSP 468 Study Group
Oct 14, 2009·Archives of Neurology·Alberto AscherioUNKNOWN Parkinson Study Group DATATOP Investigators
Oct 24, 2003·Neurobiology of Disease·Gerda AndringaAlexander R Cools
Oct 1, 1995·Nuclear Medicine and Biology·H F BeerP A Schubiger
Jul 20, 2000·Parkinsonism & Related Disorders·J LyytinenH Teräväinen
Mar 6, 2003·Parkinsonism & Related Disorders·K F BhattacharyaH Kaufmann
Jan 1, 1991·Acta Neurologica Scandinavica. Supplementum·H AllainH C Neukirch
Mar 22, 2013·CNS Drugs·Fabienne Sprenger, Werner Poewe
Jan 1, 1994·Fundamental & Clinical Pharmacology·R A Weeks, D J Brooks
Sep 10, 2005·Journal of Neurology·Yasuhiko BabaRyan J Uitti
Apr 21, 2007·Current Treatment Options in Neurology·Marian L Evatt
Jun 1, 1993·Free Radical Biology & Medicine·S C Bondy, C P LeBel
Aug 29, 2013·The Journal of Medicine and Philosophy·Leah McClimans
Dec 1, 1995·Journal of the Neurological Sciences·D IbarretaM S Ayuso
Aug 1, 1992·Journal of the Neurological Sciences·F J Jiménez-JiménezR Codoceo
Jul 1, 1990·Journal of the Neurological Sciences·B R BloemJ W Langston
Mar 1, 1992·Neurochemistry International·R E Heikkila, P K Sonsalla
Jun 5, 1992·European Journal of Pharmacology·M GerlachM B Youdim
Mar 1, 1991·The International Journal of Neuroscience·J A Jesberger, J S Richardson
Mar 15, 2006·Expert Review of Neurotherapeutics·Lisa M Shulman, Viveca Bhat
Aug 31, 2006·Expert Opinion on Emerging Drugs·John C Morgan, Kapil D Sethi
Oct 22, 2008·Expert Opinion on Pharmacotherapy·Matthias Löhle, Alexander Storch
Aug 6, 2013·Expert Opinion on Drug Safety·Wolfgang H Jost
Jan 5, 2002·Expert Opinion on Investigational Drugs·B Drukarch, F L van Muiswinkel
Jun 14, 2008·Expert Opinion on Investigational Drugs·Marco OnofrjAstrid Thomas
Nov 20, 2015·Drugs·Ariane Park, Mark Stacy
Sep 20, 2015·Immunology Letters·Cassandra A DeMarshallUNKNOWN Parkinson’s Study Group Investigators
Feb 1, 2015·Acta Neuropathologica Communications·Tessandra StewartJing Zhang
Feb 5, 2014·Redox Biology·Samantha GiordanoJianhua Zhang
Jul 15, 2015·Molecular Neurodegeneration·Carolina Ceballos-DiazNikolaus R McFarland

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.